



For Immediate Release

Contact: Carol Long
cdlong@cdlbiz.com
610-213-9245

Cloud Pharmaceuticals Announces World-Class Board of Directors

*Board members to help Cloud Pharmaceuticals further penetrate
the cloud-based drug design and development market*

RESEARCH TRIANGLE PARK, NC (November 5, 2014)...Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it ratified its board of directors at its annual meeting on September 16, 2014. Members of the board include Cloud Pharmaceuticals Chairman and CEO, Ed Addison, CSO Shahar Keinan, PhD, and CIO Lawrence Husick. Other members of the board include:

- Rob Armstrong, PhD – Dr. Armstrong is an independent consultant in the pharmaceutical industry. His extensive discovery and preclinical development experience is of particular value to Cloud Pharmaceuticals as it works to develop partnering relationships in the drug design and development market. Previously, he acted as VP, discovery chemistry and research technologies for Eli Lilly and Company. Prior to Lilly, he was director of small molecule discovery at Amgen and served as associate professor of biochemistry at UCLA.
- Michael Brennan, MD-PhD – Dr. Brennan is the founder, president, and former CEO of Gene Logic (NASDAQ: GLGC). His experience as successful entrepreneur for a biotech company that uses information as a key part of its business model translates especially well to Cloud Pharmaceuticals. During Dr. Brennan's time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over \$5 billion. Dr. Brennan was previously a general partner at Oxford Bioscience Partners. He also served as vice president, business development for Boehringer Mannheim Therapeutics.
- John Doll – Mr. Doll has served as the acting under secretary of commerce for intellectual property and the acting director of the United States Patent and Trademark Office (USPTO). Previously, he was commissioner for patents at the USPTO. His insight is especially beneficial to Cloud Pharmaceuticals as it advances its intellectual property-rich Inverse Design platform.
- William Haseltine, MD-PhD – Dr. Haseltine brings unprecedented experience, insight, and professional affiliations to the Cloud Pharmaceuticals' board of directors. He is an American biologist, entrepreneur, and philanthropist. He is known for his groundbreaking work on HIV/AIDS and the human genome. Dr. Haseltine was a professor at Harvard Medical School where he founded two research departments on

6 Davis Drive, Research Triangle Park, NC 27709

+1 (919) 558-1254 (Office) | +1 919.357.5319 (R&D) | +1 919.424.6894 (Business Development)

www.cloudpharmaceuticals.com

cancer and HIV/AIDS. He founded several biotechnology companies, is the president of the Haseltine Foundation for Science and the Arts, and is the chairman and president of ACCESS Health International a not-for-profit organization dedicated to improving access to high quality health worldwide.

- Michael Sikora – Mr. Sikora is a CPA and business executive. His most recent role was COO for Holland & Knight, LLP. He offers Cloud Pharmaceuticals strategic and tactical advice on a broad range of issues including merger/acquisition evaluation, due diligence and integration, and operational and financial matters.
- Kenneth A. Sorensen – Dr. Sorensen is the founder and managing partner of Array Capital Management, a capital firm in New York focused on the global life sciences sector. Dr. Sorensen was formerly a Patent Examiner at the United States Patent Office (USPTO). He earned his Ph.D. in Developmental Neuroscience and previously worked as a Damon Runyon and Amgen Fellow at the Salk Institute. His unique combination of experience benefits Cloud Pharmaceuticals in its business, investments, and scientific endeavors.
- Lex Van der Ploeg, PhD – Dr. Van der Ploeg is managing director for VDP, LLC, an independent consulting agency focused on research and development for the biotechnology and pharmaceutical industries and private investors. He has extensive academic, pharmaceutical industry and biotech experience. Dr. Van der Ploeg's ability to support R&D initiatives from a strategic and tactical perspective enables him to provide sound guidance to Cloud Pharmaceuticals as it furthers its new drug designs.

“Cloud Pharmaceuticals is poised to revolutionize the way drugs are discovered and developed. To help us achieve our goals, we need to have the strongest team in place. We believe we've accomplished that with our board of directors,” says Ed Addison, Cloud Pharmaceuticals Chairman and CEO. “Each board member brings an impressive resume and base of experience that we can draw upon from both strategic and managerial perspective. Plus each person offers deep industry connections that we can leverage to support our partnering and outreach efforts.”

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners. For information visit www.cloudpharmaceuticals.com.

###